FFB News and Press Releases

  • Neurotech’s innovative treatment employing Encapsulated Cell Technology (ECT) demonstrated a biological effect after 12 months for people with retinitis pigmentosa (RP), Usher syndrome, and choroideremia participating in two Phase II/III clinical trials. Both trials are being funded in-part by the Foundation Fighting Blindness.
  • Dr. John Flannery, a Foundation-funded researcher, recently restored some visual ability in mice with retinitis pigmentosa by injecting a gene therapy that helps make up for the loss of photoreceptors.
  • The path to developing gene therapy treatments for retinal degenerations, and other diseases, has been an arduous one. Foundation Fighting Blindness researchers took on much of the early pioneering work in this field and, thanks to their foresight and dedication, gene therapy is emerging as one the greatest breakthroughs in medical research history. These milestones mark the progression of gene therapy for retinal degenerative diseases over two decades.
  • A new advance in gene therapy is providing hope for people with a debilitating retinal disease known as achromatopsia or day blindness. Researchers from the University of Pennsylvania have used gene therapy to successfully treat dogs with the same condition.